Healthcare Affordability Access
Expert articles and analysis related to healthcare affordability access.
AI Summary — Last 24 Hours
HHS OIG scrutiny of Medicare Advantage prior authorization intensified, with new findings that the three largest MA organizations denied long-term acute care and inpatient rehabilitation requests at among the highest rates—reinforcing hospital and beneficiary concerns that MA utilization management is restricting access to post-acute care central to value-based discharge planning and total-cost accountability. At the same time, KFF’s analysis of MA rebate dynamics shows how MA plans can use Medicare payment rebates to buy down Part D premiums and cost sharing, widening the competitive gap with stand-alone Part D plans and sharpening policy tensions for CMS over affordability, risk selection, and benefit design in MA-PD versus traditional Medicare drug coverage ([HHS OIG on MA denials](https://news.google.com/rss/articles/CBMilgJBVV95cUxNTFVwc3oyWjhoSkFyMDRPaEhCbGpBR0ZzdnN6b2VGQmhMeHBQTmdlM3loYXR4Tm5rdUZjWXVZMURNZTI1TzVGVDFWdEdNd2R4MkRXOFRqRjRnR1VhOVBBcE13cHVmVEp6ZmIxcC01XzJCbDAzN3M5Um5TdUpTVUN2WE1WWmZRc3JvRUNFR3dMOWNjU0Z6blRwUlNobWlvZkJSX3dubm
Related Articles
Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program
From newsletter: Public Policy Cornerstones of America’s Financialized Health Care System Which public policies corporatized the US health care system? ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ...
Illinois lawmakers try to appease both sides in drug pricing controversy
Illinois lawmakers try to appease both sides in drug pricing controversy  The State Journal-Register
How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system...
Why Some Employers Are Scaling Back GLP-1 Coverage in 2027
Why Some Employers Are Scaling Back GLP-1 Coverage in 2027Â Â Pharmaceutical Commerce
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market  KFF
Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans. This brief analy...
How Has Insurer Participation in the ACA Marketplaces Changed in 2026?
This brief features maps showing how insurer participation has changed at the state and county level from 2025 to 2026 as well as insight into the number of issuers offering plans at specific metal le...
Levrx Adds A New Feature To Manage Specialty Medications Across Pharmacies, Programs & Vendors - open minds
Levrx Adds A New Feature To Manage Specialty Medications Across Pharmacies, Programs & Vendors  open minds